Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 11:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,832 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo- C Clear all
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Phase 1, First-in-human Study of VX-433

NCT07584434
View directory record Official record
Conditions
Narcolepsy Type 1 (NT1)
Interventions
VX-433, Placebo, Midazolam, Bupropion
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 19, 2026, 11:32 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety and Immunogenicity of an Oral HIV Vaccine in Healthy, HIV-uninfected Adults

NCT02771730
View directory record Official record
Conditions
Healthy Volunteer, HIV Vaccine
Interventions
Ad4-mgag, Ad4-EnvC150, Placebo Comparator, AIDSVAX B/E
Biological · Other
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years to 49 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated Mar 18, 2024 · Synced Oct 19, 2026, 11:32 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Determine the Safety and Efficacy of TG-C in Subjects With Kellgren and Lawrence Grade 2 or 3 OA of the Knee

NCT03203330
View directory record Official record
Conditions
Degenerative Osteoarthritis
Interventions
TG-C, Placebo Control
Biological
Lead sponsor
Kolon TissueGene, Inc.
Industry
Eligibility
40 Years and older
Enrollment
535 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
44
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 19, 2026, 11:32 AM EDT
Terminated Phase 4 Interventional Results available

Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis

NCT02308111
View directory record Official record
Conditions
Liver Cirrhosis, Biliary
Interventions
Obeticholic Acid (OCA), Placebo
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
43
States / cities
Phoenix, Arizona • Los Angeles, California • Rialto, California + 32 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2023 · Synced Oct 19, 2026, 11:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults

NCT04966871
View directory record Official record
Conditions
Malaria
Interventions
PfSPZ Vaccine, PfSPZ Challenge (7G8) for CHMI, Normal Saline
Biological · Other
Lead sponsor
Sanaria Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 18, 2022 · Synced Oct 19, 2026, 11:32 AM EDT
Completed Phase 2 Interventional

SB497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With Thrombocytopenia Due To Hepatitis C

NCT00110799
View directory record Official record
Conditions
Hepatitis C, Chronic, Hepatitis C, Thrombocytopenia
Interventions
SB497115, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
9
States / cities
Denver, Colorado • Boston, Massachusetts • Detroit, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2012 · Synced Oct 19, 2026, 11:32 AM EDT
Recruiting Phase 3 Interventional

Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab

NCT05877963
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Ublituximab, Placebo
Biological · Drug
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
41
States / cities
Birmingham, Alabama • Cullman, Alabama • Orange, California + 34 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 19, 2026, 11:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacodynamic Biomarkers to Support Biosimilar Development: Interleukin-5 Antagonists

NCT04183192
View directory record Official record
Conditions
Healthy Subjects, Pharmacokinetics, Pharmacodynamics
Interventions
Mepolizumab, Reslizumab, Placebo
Biological
Lead sponsor
Food and Drug Administration (FDA)
Federal
Eligibility
18 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 22, 2024 · Synced Oct 19, 2026, 11:32 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Partial Double-Blind, Placebo-Controlled Study to Assess the Effect of Anastrozole on the Endometrium in Healthy Volunteers

NCT00467493
View directory record Official record
Conditions
Menstruation Disorders
Interventions
Anastrozole
Drug
Lead sponsor
Meditrina Pharmaceuticals
Industry
Eligibility
25 Years to 45 Years · Female only
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
2
States / cities
Kalamazoo, Michigan • Southfield, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 3, 2009 · Synced Oct 19, 2026, 11:32 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Heat Therapy and Omega 3 on Cardio-Metabolic Health

NCT04051034
View directory record Official record
Conditions
Hypertension
Interventions
Omega 3, Placebo
Dietary Supplement · Other
Lead sponsor
Texas Tech University
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Aug 14, 2019 · Synced Oct 19, 2026, 11:32 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Validating a New Non-invasive Approach to Testing Lidocaine Effectiveness

NCT03680885
View directory record Official record
Conditions
ADHD, Controls
Interventions
Lidocaine gel, Placebo, Injected lidocaine
Drug
Lead sponsor
PhenoSolve, LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 15, 2020 · Synced Oct 19, 2026, 11:32 AM EDT
Completed Phase 2 Interventional

A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP)

NCT04993768
View directory record Official record
Conditions
Progressive Supranuclear Palsy
Interventions
TPN-101, 100 mg/day, TPN-101, 200 mg/day, TPN-101, 400 mg/day, Placebo
Drug
Lead sponsor
Transposon Therapeutics, Inc.
Industry
Eligibility
41 Years to 86 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
14
States / cities
Phoenix, Arizona • La Jolla, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 19, 2026, 11:32 AM EDT
Completed Phase 3 Interventional Results available

Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Benefit Subjects With Hepatitis C Liver Disease

NCT00529568
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
eltrombopag, placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
59
States / cities
Birmingham, Alabama • Tucson, Arizona • Anaheim, California + 49 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2013 · Synced Oct 19, 2026, 11:32 AM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers

Targeting ER Stress in Vascular Dysfunction

NCT04001647
View directory record Official record
Conditions
Vasodilation, Arterial Stiffness
Interventions
Acetylcholine, Sodium Nitroprusside, Ascorbic Acid
Drug
Lead sponsor
Colorado State University
Other
Eligibility
18 Years to 80 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Oct 19, 2026, 11:32 AM EDT
Completed Not applicable Interventional

Study of Glutathione, Vitamin C and Cysteine in Children With Autism and Severe Behavior Problems

NCT00889538
View directory record Official record
Conditions
Autism, Severe Behavior Disorder
Interventions
placebo, glutathione, glutathione, vit C and NAC
Drug
Lead sponsor
University of Louisville
Other
Eligibility
5 Years to 16 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 7, 2016 · Synced Oct 19, 2026, 11:32 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

The Effects of Vitamin C on Acute-Exercise in Postmenopausal Females

NCT07109115
View directory record Official record
Conditions
Females, Males, Menopause, Sedentary, Healthy Participants
Interventions
Vitamin C (Ascorbic Acid)
Dietary Supplement
Lead sponsor
University of Virginia
Other
Eligibility
45 Years and older
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 19, 2026, 11:32 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3844583 in Healthy Participants and Participants With Atopic Dermatitis

NCT05486208
View directory record Official record
Conditions
Healthy, Dermatitis, Atopic
Interventions
LY3844583, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 19, 2026, 11:32 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Probiotics for Prevention of Antibiotic Associated Diarrhea and Clostridium Difficile Associated Disease

NCT02076438
View directory record Official record
Conditions
Diarrhea
Interventions
Probiotics
Dietary Supplement
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 89 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 23, 2016 · Synced Oct 19, 2026, 11:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Multiple Dose Study Of PF-04620110 In Overweight And Obese, Otherwise Healthy Volunteers

NCT00959426
View directory record Official record
Conditions
Obesity, Overweight, Healthy
Interventions
PF-04620110, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 7, 2010 · Synced Oct 19, 2026, 11:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Effect of a Single Oral Dose of MT-7117 on the QT/QTc Interval in Healthy Subjects

NCT05241535
View directory record Official record
Conditions
Healthy Subjects
Interventions
MT-7117, moxifloxacin, Placebo
Drug
Lead sponsor
Tanabe Pharma America, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Daytona Beach, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 15, 2023 · Synced Oct 19, 2026, 11:32 AM EDT
Completed Phase 3 Interventional

ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation

NCT05021835
View directory record Official record
Conditions
Cardiovascular Risk, Chronic Kidney Disease, Inflammation
Interventions
Ziltivekimab B, Ziltivekimab C, Placebo (Ziltivekimab B), Placebo (Ziltivekimab C)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
6,385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
181
States / cities
Birmingham, Alabama • Montgomery, Alabama • Glendale, Arizona + 140 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 19, 2026, 11:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluating Whole Foods Supplementation on Cognition

NCT01672359
View directory record Official record
Conditions
Sub-optimal Cognitive Function, Sub-optimal Immune Function
Interventions
Ginkgo Synergy® and Choline, OPC Synergy® and Catalyn, Placebo
Dietary Supplement
Lead sponsor
University of Miami
Other
Eligibility
60 Years and older
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 6, 2014 · Synced Oct 19, 2026, 11:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Studies on Aldosterone and Vascular Function

NCT00700479
View directory record Official record
Conditions
Inflammation
Interventions
aldosterone, low or high sodium diet, placebo
Drug · Dietary Supplement
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 18, 2008 · Synced Oct 19, 2026, 11:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Safety and Tolerability of BMN 111 Administered to Healthy Adult Volunteers

NCT01590446
View directory record Official record
Conditions
Achondroplasia
Interventions
BMN 111, Normal Saline
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
22 Years to 45 Years · Male only
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 11, 2012 · Synced Oct 19, 2026, 11:32 AM EDT